Susquehanna International Group, LLP Phathom Pharmaceuticals, Inc. Call Options Transaction History

Susquehanna International Group, LLP

  • $560 Billion
  • Q3 2024

Call Options

13 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$10.25 - $19.5 $4.51 Million - $8.58 Million
-440,100 Reduced 95.07%
22,800 $412,000
Q2 2024

Aug 15, 2024
BUY
$8.97 - $12.05 $4.03 Million - $5.41 Million
448,800 Added 3182.98%
462,900 $4.77 Million
Q1 2024

May 07, 2024
BUY
$6.21 - $11.05 $8,073 - $14,365
1,300 Added 10.16%
14,100 $149,000
Q4 2023

Feb 14, 2024
SELL
$6.99 - $10.71 $478,116 - $732,564
-68,400 Reduced 84.24%
12,800 $116,000
Q3 2023

Nov 14, 2023
SELL
$10.26 - $15.7 $730,512 - $1.12 Million
-71,200 Reduced 46.72%
81,200 $842,000
Q2 2023

Aug 11, 2023
SELL
$7.28 - $14.32 $286,104 - $562,776
-39,300 Reduced 20.5%
152,400 $2.18 Million
Q1 2023

May 16, 2023
BUY
$6.19 - $12.36 $1.19 Million - $2.37 Million
191,700 New
191,700 $1.37 Million
Q3 2022

Nov 14, 2022
BUY
$6.46 - $12.11 $3,876 - $7,266
600 Added 0.79%
76,100 $843,000
Q2 2022

Aug 15, 2022
BUY
$6.2 - $15.5 $251,720 - $629,300
40,600 Added 116.33%
75,500 $637,000
Q1 2022

May 16, 2022
BUY
$11.55 - $20.06 $403,095 - $700,094
34,900 New
34,900 $475,000
Q3 2021

Nov 15, 2021
SELL
$30.69 - $36.83 $306,900 - $368,300
-10,000 Closed
0 $0
Q2 2021

Aug 11, 2021
SELL
$32.66 - $39.87 $26,127 - $31,895
-800 Reduced 7.41%
10,000 $339,000
Q4 2020

Feb 16, 2021
BUY
$33.22 - $50.26 $358,776 - $542,808
10,800 New
10,800 $359,000

Others Institutions Holding PHAT

# of Institutions
144
Shares Held
73.6M
Call Options Held
42.3K
Put Options Held
45.7K
View Full List

About Phathom Pharmaceuticals, Inc.

PHAT Quotes by TradingView
  • Ticker PHAT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,175,200
  • Market Cap $344M
  • Description
  • Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...
More about PHAT
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email